FSSAI notices Dr. Reddy’s, Nestle Health Science over claims
In short
FSSAI issued a notice to Dr. Reddy’s, Nestle Health Science and some e-commerce players over “Celevida GLP+” on online platforms. The reported issue is misleading or non-compliant advertising claims.
This matters because it could affect how the product is sold and marketed online. The reporting does not say what action FSSAI will take next.
What the reporting says
FSSAI issued a notice to Dr. Reddy’s, Nestle Health Science and e-commerce players over alleged misleading claims for “Celevida GLP+” on online platforms. The publisher-supplied summary says the notice concerns non-compliant advertising and claims, but it does not state the full contents of the notice or any enforcement outcome. Business Standard separately said the regulator suspended one retailer’s licence and sought prosecution in another case.
Why it matters
FSSAI issued a notice to Dr. Reddy’s, Nestle Health Science and e-commerce players over alleged non-compliant advertising for “Celevida GLP+” on online platforms. The reporting says the regulator also took separate enforcement steps against other firms, but it does not connect those actions to the notice. The immediate impact is regulatory scrutiny for the companies involved, while the next step and any penalties are not stated.